CX 1739
Alternative Names: CX-1739Latest Information Update: 04 Jun 2024
At a glance
- Originator Cortex Pharmaceuticals
- Developer Cortex Pharmaceuticals; National Institute of Drug Abuse; RespireRx Pharmaceuticals
- Class Antidementias; Mood stabilisers; Respiratory stimulants
- Mechanism of Action AMPA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Respiratory insufficiency; Sleep apnoea syndrome
- Preclinical Spinal cord injuries
- Discontinued Attention-deficit hyperactivity disorder; Substance-related disorders
Most Recent Events
- 29 May 2024 RespireRx Pharmaceuticals plans to file an IND application for phase II trial in Spinal cord injuries prior to 4Q 2024
- 29 May 2024 RespireRx Pharmaceuticals plans a phase-IIA/B trial in Spinal cord injuries in 4Q 2024
- 20 Mar 2024 Pharmacodynamics data from a preclinical trial in Spinal cord injuries released by RespireRx Pharmaceuticals